Delta variant's invasion trick to evade immune response


Thursday, 21 April, 2022

Delta variant's invasion trick to evade immune response

COVID-19’s Delta variant may use a novel invasion method to evade the body’s immune response, causing more damage to the brain, intestine and kidneys than the original Wuhan COVID strain, a Griffith University study has found.

Led by Menzies Health Institute Queensland’s Dr Xiang Liu, the researchers compared the original Wuhan strain with Delta in mice models and found distinct immune response patterns between the ancestral SARS-CoV-2 and Delta variant.

“In our study, we found that Delta infection induced the similar levels of disease symptoms as the ancestral SARS-CoV-2 but with significant dissemination and tissue damage to multiple organs including tissue lesions in the brain and intestinal wall thinning,” Liu said.

“Surprisingly, the numbers of leukocytes (white blood cells) recruited to the lung tissue during Delta infection were significantly lower.

“These observations suggest the Delta variant may have yet unknown immune evasion mechanisms which increases infection. We hope to discover how this biological process happens with future research.”

Dr Adam Taylor, who co-led the study, said as SARS-CoV-2 variants were continually emerging it was critical to study disease progress to understand and manage clinical threats.

“These results will help shed light on the changing disease profile of COVID-19 and may guide therapeutic interventions for emerging SARS-CoV-2 variants,” he said.

The study has been published in mBio.

Image credit: ©stock.adobe.com/au/charnsitr

Related News

Australia invests further $14.6 million in national allergy research

Further funding until June 2028 for the National Allergy Centre of Excellence (NACE) and the...

Balcony and nearby construction activities linked to RPA deaths

The investigation report into the Royal Prince Alfred Hospital fungal outbreak that occurred in...

$1bn vaccine and antivenom manufacturing facility opens

A $1 billion cell-based influenza vaccine and antivenom manufacturing facility has opened in...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd